Abbreviations used: BDI = bile duct incannulation; BDL = bile duct ligation; cAMP = adenosine 3', 5'-monophosphate; PCNA = proliferating cellular nuclear antigen; r-VEGF-A = recombinant-VEGF-A; VEGF = vascular endothelial growth factor.
INTRODUCTION
Cholangiocytes, the epithelial cells lining the intrahepatic biliary epithelium (6), modify bile, originally secreted at the bile canaliculus (43), by a series of absorptive and secretory events regulated by a number of factors including gastrointestinal hormones/peptides, bile salts and nerve receptor agonists (4-7, 11, 31, 38). The gastrointestinal hormone secretin increases ductal secretion by interaction with specific receptors (expressed only by cholangiocytes) (10), an interaction that induces an increase in intracellular adenosine 3',5'-monophosphate (cAMP) levels (4, 7, 25, 26, 31, 38).
Increased intracellular cAMP levels induces activation of the CFTR Cl -channels (9, 31) and Cl -/HCO 3 -exchanger activity (7, 11, 31), a series of events that leads to secretinstimulated bile and bicarbonate secretion (5, 26).
In normal liver, cholangiocytes have low basal DNA synthesis (4, 51). However, cholangiocytes proliferate in a number of experimental models of cholestasis including bile duct ligation (BDL) (4, 5, 12, 25, 37, 38). Cholangiocyte proliferation in the course of cholangiopathies compensates for the loss of injured ducts and, in fact, proliferating cholangiocytes display enhanced basal and secretin-stimulated ductal secretory activities (4-6, 26, 31, 38). A number of studies in rats (3-6, 8-10, 25, 36-40) and humans (45) have shown that changes in cholangiocyte proliferation are associated with parallel modifications in secretin receptor gene expression, secretin-stimulated cAMP levels and secretin-induced bile and bicarbonate secretion. For example, we have shown in rats that in pathological conditions associated with increased cholangiocyte proliferation (e.g., following BDL or partial hepatectomy) (4, 5, 25, 38), there is enhanced secretin receptor gene expression and augmented basal and secretin-stimulated cAMP levels and bile and bicarbonate secretion. On the other hand, reduced cholangiocyte proliferation or enhanced cholangiocyte loss (e.g., following vagotomy, acute administration of CCl 4 or depletion of endogenous bile acid pool) (3, 36, 39) is coupled with decreased basal and secretin-stimulated cAMP levels and bile and bicarbonate secretion. In humans, an impaired response to secretin was observed in cholestatic conditions (45).
Cholangiocyte proliferation is regulated by neuropeptides, hormones and growth factors including vascular endothelial growth factor (VEGF) (6, 21, 37). Rat cholangiocytes express the protein for VEGF-A and secrete VEGF, and express the VEGF receptor subtypes, VEGFR-2 and VEGFR-3 but not VEGFR-1 (21). VEGF secretion is enhanced in proliferating cholangiocytes from BDL rats, where it stimulates, by autocrine mechanisms, cholangiocyte proliferation (21).
The peribiliary plexus (PBP) stems from the hepatic artery, nourishes the biliary tree and sustains a contercurrent of substances reabsorbed from bile toward hepatocytes (23). A true microvascular plexus vascularizes larger ducts, whereas around the smaller ducts the plexus gets progressively simpler (up to a single capillary) and thinner (23). In normal rats, where cholangiocytes are in a quiescent status (39), ligation of the main hepatic artery by its own is not sufficient to induce bile duct damage, suggesting that accessory arteries, collateral vessels or anastomosis between PBP and portal system may overcome the interruption of arterial flow in the main hepatic artery (16, 17) . Consistently, interruption of blood flow to intrahepatic bile ducts (by short-term ligation of the hepatic artery of normal guinea pigs) does not alter cholangiocyte secretion (50). The extrahepatic and intrahepatic PBP in the normal liver has been the subject of a number of studies using three-dimensional observations (22-24). Changes in intrahepatic bile duct mass are always associated with changes of the PBP architecture (22, 23). After BDL, the increase in intrahepatic bile duct mass is followed by a parallel growth of the PBP (23), which is fundamental in sustaining the enhanced nutritional and functional demands of proliferating cholangiocytes (4-6). Nevertheless, the proliferation of the PBP occurs only after the hyperplasia of the intrahepatic biliary epithelium (23). This finding suggests a cross-talk mechanism between cholangiocytes and endothelial cells, an interaction that mediates the adaptive changes of these cells during liver damage.
However, limited information exists on the role of blood supply through the hepatic artery in pathological conditions characterized by cholangiocyte proliferation/loss (14, 48) . This concept has clinical implications since ischemic bile duct lesions are considered possible causes of cholestatic disorders, in particular after liver transplantation, hepatic surgery and intra-arterial chemotherapy (13, 15) .
MATERIAL AND METHODS

Materials
Reagents were purchased from Sigma Chemical Co. 
Animal Models
Male Fischer 344 rats (150 to 175 gm) were purchased from Charles River (Wilmington, MA). The animals were kept in a temperature-controlled environment (22˚C) with a 12-hour light-dark cycle and fed ad libitum rat chow. The studies were performed in: (i) normal rats and normal rats + HAL (for evaluation of cholangiocyte apoptosis and proliferation in liver sections); (ii) 1 week BDL (for isolation of cells) (4, 5) or bile duct incannulated (BDI, for bile collection) (5) rats; and (iii) rats that (immediately after BDL or BDI + HAL) were treated by IP implanted Alzet osmotic minipumps with 0.2% bovine serum albumin (BSA) or r-VEGF-A (2.5 nmol/kg/hour with 0.2% BSA) for 1 week. The dose (nM range) of r-VEGF-A administered to BDL + HAL rats was chosen according to the concentration (nM range) of VEGF found in the serum of rats and human in other studies (12, 52) . The group of BDL + HAL rats was studied since we observed impaired secretion of VEGF in BDL cholangiocytes after HAL. Since we observed impaired secretion of VEGF in BDL cholangiocytes after HAL, the group of BDL + HAL + VEGF rats was chosen to evaluate whether the effects of HAL observed in BDL rats are prevented by chronic administration of r-VEGF-A. BDL and BDI were performed as described (5). HAL was performed as described (29). Before each procedure, animals were anesthetized with sodium pentobarbital (50 mg/kg body weight, IP). Study protocols were performed in compliance with the institution guidelines.
Isolation of Hepatocytes and Cholangiocytes
Hepatocytes were isolated as described (2) . Cholangiocytes (97-100% pure by -GT histochemistry) (46) were purified by immunoaffinity separation (4, 28). Cell number and viability (greater than 97%) was assessed by trypan blue exclusion.
Body Weight, Liver Morphology, Necrosis, Inflammation and Peri-ductular
Fibrosis
We evaluated the effect of BDL, HAL and HAL + r-VEGF-A administration to BDL + HAL rats on body weight, liver morphology, necrosis, inflammation and peri-ductular fibrosis. We evaluated, by H&E staining of paraffin-embedded liver sections (4 µm thick, 6 slides evaluated for each group), the degree of portal inflammation (18), necrosis and lobular morphology (disarrangement of hepatocytes). At least 10 different portal areas were evaluated. Following H&E staining, liver sections were examined in a coded fashion with an Olympus BX-40 (Tokyo, Japan) microscope equipped with a camera.
We evaluated, by Masson's trichrome staining of paraffin-embedded liver sections (4 µm thick, 6 slides evaluated for each group), the degree of fibrosis around proliferating ducts from BDL, BDL+HAL and BDL+HAL+r-VEGF-A treated rats. At least 6 different microscopic fields (10X and 20X) for each slide were analysed in a coded fashion with an Olympus BX-51 microscope (Tokyo, Japan) equipped with a Videocam (Spot Insight, Diagnostic Instrument, Inc. Sterling Heights, MI) and processed with an Image Analysis System (IAS -Delta Sistemi, Roma-Italy). Peri-ductular fibrosis was measured as the volume fraction of the entire liver tissue specimen (% volume fraction of the green stained collagen fibres less volume fraction occupied respectively by portal triads and by the parenchyma).
Evaluation of Liver Microcirculation
Following anesthesia, the abdomen of the selected animal was opened and a cannula (Inpharven diameter 1.4 mm, Inphardial, Italy) was inserted into the aorta and fixed with 2 silk ties. Before flushing the vascular bed with heparinized saline solution (23), the thorax was opened and the right atrium incised to allow the efflux of the perfusate. When the outflow fluid appeared clear of blood, Mercox CL2R resin, diluted with methyl methacrylate monomer (4:1) (34) and mixed with a standard amount of its catalyzer (up to 2 ml catalyzer per 20 ml of base compound), was injected at room temperature. A constant pressure control was maintained (by a CONEL electronic manometer, Rome, Italy) through the lateral port of the cannula's injection valve until resin polymerization was visible. The animals were left at room temperature for 24 hours and after the polymerization of the resin, the livers were removed and macerated in 20% NaOH solution at room temperature. After rinsing in distilled water, the liver casts were placed in 5% trichloroacetic acid solution to free the cast from tissue remnants. The casts were isolated, frozen in distilled water and frozen-dried. They were then glued onto stubs by means of Silver Dag and gold coated in an Sl50 sputterer (Edwards, London, UK). The prepared casts were examined with a Hitachi S4000 Field Emission scanning electron microscope (Hitachi Ltd., Tokyo, Japan) operating at 5-8 kV (23).
Evaluation of Cholangiocyte VEGF Protein Expression and Secretion
Protein expression for VEGF-A, VEGFR-1, VEGFR-2 and VEGFR-3 was evaluated by immunohistochemistry in liver sections (5 µm thick, 6 slides evaluated per group) mounted on glass slides coated with 0.1% poly-L-lysine. Following staining, sections were analyzed in a coded fashion with an Olympus BX-51 microscope (Tokyo, Japan) equipped with a Videocam (Spot Insight, Diagnostic Instrument, Inc. Sterling Heights, MI) and processed with an Image Analysis System (IAS -Delta Sistemi, Roma-Italy).
The intensity and distribution of immunostaining were assessed in a coded fashion.
Following isolation, hepatocytes or cholangiocytes (1x10 6 ) were incubated at 37 o C for zero or six hours, centrifuged at 1,500 rpm for 10 minutes, the supernatant (100 µl)
transferred to a tube and analyzed for VEGF concentration by ELISA (Peninsula Laboratories, Inc, San Carlos, CA). VEGF secretion (ng/1x10 6 cells) was calculated as the difference between the amount of VEGF detected at six hours and the amount detected at time zero.
Cholangiocyte Apoptosis and Proliferation
We evaluated cholangiocyte and hepatocyte apoptosis by TUNEL analysis (39) in liver 
Measurement of Basal and Secretin-Stimulated Ductal Secretion
At the functional level, cholangiocyte proliferation was evaluated by measurement of basal and secretin-stimulated cAMP levels (32, 39) in purified cholangiocytes and bile and bicarbonate secretion (5) in bile fistula rats, two functional indices of cholangiocyte proliferation) (4, 5, 20, 25, 26, 36-39).
For the measurement of cAMP levels, purified cholangiocytes were incubated for 1 hour at 37°C (32) and incubated for 5 minutes at room temperature (32) with 0.2% BSA (basal) or 100 nM secretin with 0.2% BSA. Intracellular cAMP levels were measured by commercially available RIA kits (Amersham Life Science) (32).
Following anesthesia, rats were surgically prepared for bile collection as described by us (5). One jugular vein was incannulated with a plastic cannula to infuse either Krebs Ringer Henseleit (KRH) or secretin (100 nM) dissolved in KRH. Biliary bicarbonate concentration (measured as total CO 2 ) was determined by an ABL 520 Blood Gas System (Radiometer Medical A/S, Copenhagen, Denmark).
Statistical Analysis
All data are expressed as mean ± SEM. Differences between groups were analyzed by the Student unpaired t test when two groups were analyzed and analysis of variance (ANOVA) when more than two groups were analyzed, followed by an appropriate post hoc test.
RESULTS
Effects of HAL and r-VEGF-A on Body Weight, Liver Morphology, Necrosis and
Inflammation and Peri-ductular Fibrosis
No changes in body weight were observed among BDL (161.7 ± 4.0 gm), BDL + HAL (172.3 ± 7.0 gm) and BDL + HAL + r-VEGF-A (165.6 ± 5.6 gm) rats. There were no differences in the amount of lobular damage among BDL rats and rats that (immediately after BDL + HAL) were treated with 0.2% BSA or r-VEGF-A for 1 week (see representative Figure 1 a and Table 1 ). The degree of necrosis, portal inflammation and the % volume fraction of peri-ductular fibrosis observed in BDL rats were reduced in BDL+HAL compared to the value of BDL rats ( Figure 1 a-b and Table 1 ). Following the administration of r-VEGF-A to BDL + HAL rats, the degree of necrosis, portal inflammation and the % volume fraction were similar than that of the BDL rat (see representative Figure 1 a-b and Table 1 ).
Effect of HAL and r-VEGF-A on the Peribiliary Plexus and VEGF Expression
The peribiliary plexus, observed in BDL rats (23), was not demonstrated in BDL + HAL rats by scanning electron microscopy corrosion cast technique. We did not observe PBP in BDL+HAL rats because the PBP is nourished by the hepatic artery. In normal rats, Table 2 ). VEGFR-1 was not expressed by cholangiocytes (Table 2) . VEGF-A was predominantly expressed by hepatocytes of centrolobular zone (Table 3) . Hepatocyte VEGF-A protein expression did not increase significantly in BDL liver sections compared to normal sections, decreased after HAL and returned to values similar to those of BDL rats (Table 3) .
Normal rat hepatocytes and cholangiocytes secrete VEGF ( Secretin stimulated bile flow, bicarbonate concentration and secretion of BDI rats (Table   5 ). In HAL + BDL rats, secretin did not increase bile flow and bicarbonate concentration and secretion of BDI rats (Table 5) . Administration of r-VEGF-A prevented the inhibition of secretin-stimulated bile and bicarbonate concentration and secretion, which were similar to that of BDL rats (Table 5) .
DISCUSSION
The study demonstrates that in BDL rats, HAL: (i) induced the absence of the peribiliary plexus; (ii) decreased the immunolocalization of VEGFR-2 and VEGFR-3 receptors and VEGF-A in liver sections, and VEGF secretion in purified cholangiocytes and hepatocytes; (iii) induced loss of intrahepatic bile ducts in BDL but not normal rats, caused by both increased apoptosis and decreased cholangiocyte proliferation; no changes in hepatocyte apoptosis and proliferation were observed in BDL rats and rats that 
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Figure 1
[a] Light microscopy of liver sections (stained with H&E) from 1 week BDL rats, and rats that (immediately after BDL + HAL) were treated by IP implanted Alzet osmotic minipumps with 0.2% BSA or r-VEGF-A with 0.2% BSA for 1 week.
There were no significant differences in the amount of lobular damage in liver sections from 1 week BDL rats, and rats that (immediately after BDL + HAL) were treated by IP implanted Alzet osmotic minipumps with 0.2% BSA or r-VEGF-A for 1 week (for quantitative data see Table 1 ). In BDL + HAL rats, the degree of necrosis and portal inflammation decreases compared to BDL rats (for quantitative data see Table 1 ).
Following the administration of r-VEGF-A to BDL + HAL rats, the degree of necrosis and portal inflammation was similar than that of the BDL rat (for quantitative data see Table 1 ). Orig. magn., x80.
[b] Light microscopy of liver sections (Masson's stain) from 1 week BDL rats, and rats that (immediately after BDL + HAL) were treated by IP implanted Alzet osmotic minipumps with 0.2% BSA or r-VEGF-A with 0.2% BSA for 1 week. The % volume fraction of peri-ductular fibrosis observed in BDL rats was reduced in BDL+HAL rats compared to the value of BDL rats. Following the administration of r-VEGF-A to BDL + HAL rats, the % volume fraction was similar than that of the BDL rat (for quantitative data see Table 1 ). Orig. magn., x20. Table 2 . Immunohistochemical evaluation of cholangiocyte VEGF-A, VEGFR-1, VEGFR-2 and VEGFR-3 expression in liver sections from 1 week BDL rats, and rats that 98.6 ± 6.5
138.7 ± 6.5 # 38.1 ± 1. 
